Homology modeling of opioid receptor-ligand complexes using experimental constraints

AAPS Journal

Volumn 7, Issue 2, 2005, Pages

  Pogozheva, Irina D ^a   Przydzial, Magdalena J ^a   Mosberg, Henry I ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Ligand docking; Modeling; Opioid ligands; Opioid receptors; Pharmacophore model

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 4 ANILINOPIPERIDINE DERIVATIVE; ALKALOID DERIVATIVE; ARYLACETAMIDE DERIVATIVE; BENZOMORPHAN DERIVATIVE; BIMORPHINAN DERIVATIVE; DELTA OPIATE RECEPTOR; DYNORPHIN A DERIVATIVE; ETORPHINE; KAPPA OPIATE RECEPTOR; MEFENTANYL; METHADONE DERIVATIVE; MORPHINE DERIVATIVE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NALTRINDOLE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; OPIATE RECEPTOR AFFECTING AGENT; ORIPAVINE; OXYMORPHINDOLE; PEPTIDE; PEPTIDE DERIVATIVE; PHENYLPIPERAZINE DERIVATIVE; PHENYLPIPERIDINE DERIVATIVE; RHODOPSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACCURACY; BINDING AFFINITY; BINDING SITE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CORRELATION ANALYSIS; CROSS LINKING; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; LIGAND BINDING; METAL BINDING; MOLECULAR MODEL; MUTAGENESIS; NONHUMAN; PROBLEM SOLVING; PROTEIN CONFORMATION; RELIABILITY; REVIEW; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; THEORETICAL MODEL;

ANALGESICS, OPIOID; ANIMALS; HUMANS; LIGANDS; MODELS, MOLECULAR; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID;

EID: 30644458763     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070243     Document Type: Review

References (159)

1. Kieffer BL. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol. 1995;15:615-635.
2. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem. 2004;73:953-990.
3. Pasternak GW. Multiple opiate receptors: déjà vu all over again. Neuropharmacology. 2004;47:312-323.
4. Vaccarino AL, Kastin AJ. Endogenous opiates: 2000. Peptides. 2001;22:2257-2328.
5. Hruby VJ, Agnes RS. Conformation-activity relationships of opioid peptides with selective activities at opioid receptors. Biopolymers. 1999;51:391-410.
6. Mansour A, Hoversten MT, Taylor LP, Watson SJ, Akil H. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res. 1995;700:89-98.
7. Mosberg HI, Hurst R, Hruby VJ, et al. Conformationally constrained cyclic enkephalin analogs with pronounced delta opioid receptor agonist selectivity. Life Sci. 1983,32:2565-2569.
8. Pelton JT, Gulya K, Hruby VJ, Duckles S, Yamamura HI. Somatostatin analogs with affinity for opiate receptors in rat brain binding assay. Peptides. 1985;6:159-163.
9. Pelton JT, Kazmierski W, Gulya K, Yamamura HI, Hruby VJ. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986;29:2370-2375.
10. Kawasaki AM, Knapp RJ, Walton A, et al. Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions 1, 6, 7, 8, and 10. Int J Pept Protein Res. 1993;42:411-419.
11. Meyer JP, Collins N, Lung FD, et al. Design, synthesis, and biological properties of highly potent cyclic dynorphin A analogues: analogues cyclized between positions 5 and 11. J Med Chem. 1994;37:3910-3917.
12. Arttamangkul S, Murray TF, DeLander GE, Aldrich JV. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 1. Conformational constraint in the "message" sequence. J Med Chem. 1995;38:2410-2417.
13. Lung FD, Collins N, Stropova D, et al. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphin A(1-11)-NH2. J Med Chem. 1996;39:1136-1141.
14. Eguchi M. Recent advances in selective opioid receptor agonists and antagonists. Med Res Rev. 2004;24:182-212.
15. Okada T, Ernst OP, Palczewski K, Hofmann KP. Activation of rhodopsin: new insights from structural and biochemical studies. Trends Biochem Sci. 2001;26:318-324.
16. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF. Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol. 2004;343:1409-1438.
17. Flower DR. Modeling G-protein-coupled receptors for drug design. Biochim Biophys Acta. 1999;1422:207-234.
18. Flippen-Anderson JL, George C, Bertha CM, Rice KC. X-ray structure of potent opioid receptor ligands: etonitazene, cis-(+)-3-methylfentanyl, etorphine, diprenorphine, and buprenorphine. Heterocycles. 1994;39:751-766.
19. Urbanczyk-Lipkowska Z, Etter MC, Lipkowski AW, Portoghese PS. The crystal structure of a bimorphinan with highly selective kappa opioid receptor antagonist activity. J Mol Struct. 1987;159:287-295.
20. Griffin JF, Larson DL, Portoghese PS. Crystal structures of alpha- and beta-funaltrexamine: conformational requirement of the fumaramate moiety in the irreversible blockage of mu opioid receptors. J Med Chem. 1986;29:778-783.
21. Calderon SN, Rice KC, Rothman RB, et al. Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4- Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80) and related novel nonpeptide delta opioid receptor ligands. J Med Chem. 1997;40:695-704.
22. Lavecchia A, Greco G, Novellino E, Vittorio F, Ronsisvalle G. Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations. J Med Chem. 2000;43:2124-2134.
23. Doi M, Ishida T, Inoue M. Conformational characteristics of opioid kappa-receptor agonist: crystal structure of (5S,7S,8S)-(-)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec- 8-yl]benzeneacetamide (U69,593), and conformational comparison with some kappa-agonists. Chem Pharm Bull (Tokyo). 1990;38:1815-1818.
24. Subramanian G, Patrelini MG, Portoghese PS, Ferguson DM. Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000;43:381-391.
25. Mosberg HI, Fowler CB. Development and validation of opioid ligand-receptor interaction models: the structural basis of mu vs delta selectivity. J Pept Res. 2002;60:329-335.
26. Przydzial MJ, Pogozheva ID, Andrews SM, et al. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the κ-opioid receptor. J Pept Res. 2005;65:333-342.
27. Mosberg HI, Omnaas JR, Medzihradsky F, Smith CB. Cyclic, disulfide- and dithioether-containing opioid tetrapeptides: development of a ligand with high delta opioid receptor selectivity and affinity. Life Sci. 1988;43:1013-1020.
28. 1 replacements in the cyclic δ receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13). J Med Chem. 1994a; 37:4371-4383.
29. 3 replacements in the cyclic δ-receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13). J Med Chem. 1994b; 37:4384-4391.
30. Mosberg HI, Dua RK, Pogozheva ID, Lomize AL. Development of a model for the δ-opioid receptor pharmacophore. 4. Residue 3 dehydrophenyl-alanine analogs of Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13) confirm required gauche orientation of aromatic sidechain. Biopolymers. 1996;39:287-296.
31. 1H NMR data. J Am Chem Soc. 1994;116:429-436.
32. Ho JC. Development of a Model for the δ-opioid Receptor Pharmacophore [dissertation]. Ann Arbor, MI: University of Michigan; 1997.
33. McFadyen IJ, Ho JC, Mosberg HI, Traynor JR. Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]NH2 (Et): effects on opioid receptor binding and activation. J Pept Res. 2000;55:255-261.
34. Fowler CB III, Pogozheva ID III, Lomize AL III, LeVine H III, Mosberg HI. Complex of an active μ-opioid receptor with cyclic peptide agonist modeled from experimental constraints. Biochemistry. 2004a;43:15796-15810.
35. Mosberg HI. Complementarity of delta opioid ligand pharmacophore and receptor models. Biopolymers. 1999;51:426-439.
36. Law PY, Loh HH. Regulation of opioid receptor activities. J Pharmacol Exp Ther. 1999;289:607-624.
37. Chaturvedi K, Christoffers KH, Singh K, Howells RD. Structure and regulation of opioid receptors. Biopolymers. 2000;55:334-346.
38. Chavkin C, McLaughlin JP, Celver JP. Regulation of opioid receptor function by chronic agonist exposure: constitutive activity and desensitization. Mol Pharmacol. 2001;60:20-25.
39. Coward P, Wada HG, Falk MS, et al. Controlling signaling with a specifically designed Gi-coupled receptor. Proc Natl Acad Sci USA. 1998;95:352-357.
40. Pogozheva ID, Lomize AL, Mosberg HI. Opioid receptor 3-dimensional structures from distance geometry calculations with hydrogen bonding constraints. Biophys J. 1998;75:612-634.
41. Surratt CK, Johnson PS, Moriwaki A, et al. Mu opiate receptor: charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J Biol Chem. 1994;269:20548-20553.
42. Befort K, Tabbara L, Bausch S, Chavkin C, Evans C, Kieffer BL. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Mol Pharmacol. 1996a;49:216-223.
43. Befort K, Tabbara L, Kling D, Maigret B, Kieffer BL. Role of aromatic transmembrane residues of the delta-opioid receptor in ligand recognition. J Biol Chem. 1996b;271:10161-10168.
44. Befort K, Zilliox C, Filliol D, Yue S, Kieffer BL. Constitutive activation of the delta opioid receptor by mutations in transmembrane domains III and VII. J Biol Chem. 1999;274:18574-18581.
45. Bot G, Blake AD, Li S, Reisine T. Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist. J Pharmacol Exp Ther. 1998a;284:283-290.
46. Bot G, Blake AD, Li S, Reisine T. Mutagenesis of a single amino acid in the rat mu-opioid receptor discriminates ligand binding. J Neurochem. 1998b;70:358-365.
47. Spivak CE, Beglan CL, Seidleck BK, et al. Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity. Mol Pharmacol. 1997;52:983-992.
48. Mansour A, Taylor LP, Fine JL, et al. Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study. J Neurochem. 1997,68:344-353.
49. Meng F, Ueda Y, Hoversten MT, et al. Creating a functional opioid alkaloid binding site in the orphanin FQ receptor through site-directed mutagenesis. Mol Pharmacol. 1998;53:772-777.
50. Li JG, Chen C, Yin J, et al. ASP147 in the third transmembrane helix of the rat mu opioid receptor forms ion-pairing with morphine and naltrexone. Life Sci. 1999;65:175-185.
51. Fukuda K, Terasako K, Kato S, Mori K. Identification of the amino acid residues involved in selective agonist binding in the first extracellular loop of the delta- and mu-opioid receptors. FEBS Lett. 1995;373:177-181.
52. Minami M, Onogi T, Nakagawa T, et al. DAMGO, a mu-opioid receptor selective ligand, distinguishes between mu-and kappa-opioid receptors at a different region from that for the distinction between mu-and delta-opioid receptors. FEBS Lett. 1995;364:23-27.
53. Wang JB, Johnson PS, Wu JM, Wang WF, Uhl GR. Human kappa opiate receptor second extracellular loop elevates dynorphin's affinity for human mu/ kappa chimeras. J Biol Chem. 1994;269:25966-25969.
54. Xue JC, Chen C, Zhu J, et al. Differential binding domains of peptide and non-peptide ligands in the cloned rat kappa opioid receptor. J Biol Chem. 1994;269:30195-30199.
55. Ferguson DM, Kramer S, Metzger TG, Law PY, Portoghese PS. Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the kappa-opioid receptor does not affect dynorphin A(1-13) affinity and function. J Med Chem. 2000;143:1251-1252.
56. Bonner G, Meng F, Akil H. Selectivity of mu-opioid receptor determined by interfacial residues near third extracellular loop. Eur J Pharmacol. 2000;403:37-44.
57. Xu H, Lu YF, Partilla JS, et al. Opioid peptide receptor studies. 11. Involvement of Tyr148, Trp318 and His319 of the rat mu-opioid receptor in binding of mu-selective ligands. Synapse. 1999;32:23-28.
58. Ulens C, Van Boven M, Daenens P, Tytgat J. Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in mu-opioid receptor selectivity. J Pharmacol Exp Ther. 2000;294:1024-1033.
59. Pepin MC, Yue SY, Roberts E, Wahlestedt C, Walker P. Novel "restoration of function" mutagenesis strategy to identify amino acids of the delta-opioid receptor involved in ligand binding. J Biol Chem. 1997;272:9260-9267.
60. Valiquette M, Vu HK, Yue SY, Wahlestedt C, Walker P. Involvement of Trp-284, Val-296, and Val-297 of the human delta-opioid receptor in binding of delta-selective ligands. J Biol Chem. 1996;271:18789-18796.
61. Hjorth SA, Thirstrup K, Grandy DK, Schwartz TW. Analysis of selective binding epitopes for the kappa-opioid receptor antagonist norbinaltorphimine. Mol Pharmacol. 1995;47:1089-1094.
62. Cavalli A, Babey AM, Loh HH. Altered adenylyl cyclase responsiveness subsequent to point mutations of Asp 128 in the third transmembrane domain of the delta-opioid receptor. Neuroscience. 1999;93:1025-1031.
63. Li J, Huang P, Chen C, de Riel JK, Weinstein H, Liu-Chen LY. Constitutive activation of the mu opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression. Biochemistry. 2001;40:12039-12050.
64. Mouledous L, Topham CM, Moisand C, Mollereau C, Meunier JC. Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain. Mol Pharmacol. 2000;57:495-502.
65. DeCaillot FM, Befort K, Filliol D, Yue S, Walker P, Kieffer BL. Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation. Nat Struct Biol. 2003;10:629-636.
66. Spivak CE, Beglan CL, Zollner C, Surratt CK. Beta-Funaltrexamine, a gauge for the recognition site of wildtype and mutant H297Q mu-opioid receptors. Synapse. 2003;49:55-60.
67. Chen C, Yin J, Riel JK, et al. Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor. J Biol Chem. 1996;271:21422-21429.
68. Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. J Med Chem. 1998;41:4911-4914.
69. Larson DL, Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists. J Med Chem. 2000;43:1573-1576.
70. Fowler CB III, Pogozheva ID III, Le Vine H III, Mosberg HI. Refinement of a model of the μ-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. Biochemistry. 2004b;43:8700-8710.
71. Metzger TG, Paterlini MG, Portoghese PS, Ferguson DM. An analysis of the conserved residues between halobacterial retinal proteins and G-protein coupled receptors: implications for GPCR modeling. J Chem Inf Comput Sci. 1996;36:857-861.
72. Strahs D, Weinstein H. Comparative modeling and molecular dynamics studies of the delta, kappa and mu opioid receptors. Protein Eng. 1997;10:1019-1038.
73. Alkorta I, Loew GH. A 3D model of the delta opioid receptor and ligand-receptor complexes. Protein Eng. 1996;9:573-583.
74. Subramanian G, Paterlini MG, Larson DL, Portoghes PS, Ferguson DM. Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists. J Med Chem. 1998;41:4777-4789.
75. Paterlini G, Portoghese PS, Ferguson DM. Molecular simulation of dynorphin A-(1-10) binding to extracelluar loop 2 of the kappa-opioid receptor: a model for receptor activation. J Med Chem. 1997;40:3524-3262.
76. Filizola M, Laakkonen L, Loew GH. 3D modeling, ligand binding and activation studies of the cloned mouse delta, mu, and kappa opioid receptors. Protein Eng. 1999a;12:927-942.
77. Filizola M, Carteini-Farina M, Perez JJ. Molecular modeling study of the differential ligand-receptor interaction at the mu, delta and kappa opioid receptors. J Comput Aided Mol Des. 1999b;13:397-407.
78. Pogozheva ID, Lomize AL, Mosberg HI. The transmembrane 7 alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints. Biophys J. 1997;72:1963-1985.
79. Lomize AL, Pogozheva ID, Mosberg HI. Structural organization of G-protein-coupled receptors. J Comput Aided Mol Des. 1999;13:325-353.
80. Vaidehi N, Floriano WB, Trabanino R, et al. Prediction of structure and function of G protein-coupled receptors. Proc Natl Acad Sci USA. 2002;99:12622-12627.
81. Shacham S, Topf M, Avisar N, et al. Modeling the 3D structure of GPCRs from sequence. Med Res Rev. 2001;21:472-483.
82. Shi L, Javitch JA. The binding site of aminergic G protein-coupled receptors: the transmembrance segments and second extracellular loop. Annu Rev Pharmacol Toxicol. 2002;42-437-467.
83. Lawson Z, Wheatley M. The third extracellular loop of G-protein-coupled receptors: more than just a linker between 2 important transmembrane helices. Biochem Soc Trans. 2004;32:1048-1050.
84. Baker D, Sali A. Protein structure prediction and structural genomics. Science. 2001;294:93-96.
85. Palczewski K, Kumasaki T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 2000;289:739-745.
86. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors Mol Pharmacol. 2001;60:1-19.
87. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem. 2002;3:928-944.
88. Bissantz C, Bernard P, Hibert M, Rognan D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins. 2003;50:5-25.
89. Evers A, Klebe G. Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for succesful virtual screening. Angew Chem Int Ed Engl. 2004a;43:248-251.
90. Horn F, Bettler E, Oliveira L, Campagne F, Cohen FE, Vriend G. GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res. 2003;31:294-297.
91. Huang P, Li J, Chen C, Visiers I, Weinstein H, Liu-Chen LY. Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochemistry. 2001;40:13501-13509.
92. Sali A, Blundell TL. Comparative protein modeling by satisfaction of spatial restraints. J Mol Biol. 1993;234:779-815.
93. Fiser A, Sali A. Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol. 2003;374:461-491.
94. Peitsch MC. ProMod and Swiss-Model: internet-based tools for automated comparative protein modelling. Biochem Soc Trans. 1996;24:274-279.
95. Lund O, Frimand K, Gorodkin J, et al. Protein distance constraints predicted by neural networks and probability density functions. Protein Eng. 1997;10:1241-1248.
96. Shindyalov IN, Bourne PE. Improving alignments in HM protocol with intermediate sequences. In: Forth Meeting on the Critical Assessment of Techniques for Protein Structure Prediction; 2000:A-92.
97. Lambert C, Leonard N, De Bolle X, Depiereux E. ESyPre3D: prediction of proteins 3D structures. Bioinformatics. 2002;18:1250-1256.
98. Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. 2004;32:W526-W531.
99. Pieper U, Eswar N, Braberg H, et al. MODBASE, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res. 2004;32:D217-D222.
100. Eswar N, John B, Mirkovic N, et al. Tools for comparative protein structure modeling and analysis. Nucleic Acids Res. 2003;31:3375-3380.
101. John B, Sali A. Comparative protein structure modeling by iterative alignment, model building and model assessment. Nucleic Acids Res. 2003;31:3982-3992.
102. Rick RP, Rigoutsos I, Novotny J, Graham RM. Non-alphα-helical elements modulate polytopic membrane protein architecture. J Mol Biol. 2001;306:349-362.
103. Fiser A, Do RK, Sali A. Modeling of loops in protein structures. Protein Sci. 2000;9:1753-1773.
104. Chothia C, Lesk AM. Helix movements and the reconstruction of the haem pocket during the evolution of the cytochrome c family. J Mol Biol. 1985;182:151-158.
105. Meng EC, Bourne HR. Receptor activation: what does the rhodopsin structure tell us? Trends Pharmacol Sci. 2001;22:587-593.
106. Karnik SS, Gogonea C, Patil S, Saad Y, Takezako T. Activation of G-protein-coupled receptors: a common molecular mechanism. Trends Endocrinol Metab. 2003;14:431-437.
107. Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK. Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci USA. 2001a;98:5997-6002.
108. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science. 1996;274:768-770.
109. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK. Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J. 1997;16:6737-6747.
110. Dunham TD, Farrens DL. Conformational changes in rhodopsin: movement of helix F detected by site-specific chemical labeling and fluorescence spectroscopy. J Biol Chem. 1999;274:1683-1690.
111. Han M, Smith SO, Sakmar TP. Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6. Biochemistry. 1998;37:8253-8261.
112. Cai K, Klein-Seetharaman J, Hwa J, Hubbell WL, Khorana HG. Structure and function in rhodopsin: effects of disulfide cross-links in the cytoplasmic face of rhodopsin on transducin activation and phosphorylation by rhodopsin kinase. Biochemistry. 1999;38:12893-12898.
113. Ghanouni P, Gryczynski Z, Steenhuis JJ, et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem. 2001b;276:24433-24436.
114. Janz JM, Farrens DL. Rhodopsin activation exposes a key hydrophobic binding site for the transducin alpha-subunit C terminus. J Biol Chem. 2004;279:29767-29773.
115. Hubbell WL, Altenbach C, Hubbell CM, Khorana HG. Rhodopsin structure, dynamics, and activaiion: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv Protein Chem. 2003;63:243-290.
116. Lin SW, Sakmar TP. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry. 1996;35:11149-11159.
117. Altenbach C, Cai K, Khorana HG, Hubbell WL. Structural features and light-dependent changes in the sequence 306-322 extending from helix VII to the palmitoylation sites in rhodopsin: a site-directed spin-labeling study. Biochemistry. 1999a;38:7931-7937.
118. Altenbach C, Klein-Seetharaman J, Hwa J, Khorana HG, Hubbell WL. Structural features and light-dependent changes in the sequence 59-75 connecting helices I and II in rhodopsin: a site-directed spin-labeling study. Biochemistry. 1999b;38:7945-7949.
119. Altenbach C, Cai K, Klein-Seetharaman J, Khorana HG, Hubbell WL. Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 65 in helix TM1 and residues in the sequence 306-319 at the cytoplasmic end of helix TM7 and in helix H8. Biochemistry. 2001a;40:15483-15492.
120. Altenbach C, Klein-Seetharaman J, Cai K, Khorana HG, Hubbell WL. Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 316 in helix 8 and residues in the sequence 60-75, covering the cytoplasmic end of helices TM1 and TM2 and their connection loop CL1. Biochemistry. 2001b;40:15493-15500.
121. Gether U, Kobilka BK. G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem. 1998;273:17979-17982.
122. Devanathan S, Yao Z, Salamon Z, Kobilka B, Tollin G. Plasmon-waveguide resonance studies of ligand binding to the human beta 2-adrenergic receptor. Biochemistry. 2004;43:3280-3288.
123. Salamon Z, Cowell S, Varga E, Yamamura HI, Hruby VJ, Tollin G. Plasmon resonance studies of agonist/antagonist binding to the human delta-opioid receptor: new structural insights into receptor-ligand interactions. Biophys J. 2000;79:2463-2474.
124. Salamon Z, Hruby VJ, Tollin G, Cowell S. Binding of agonists, antagonists and inverse agonists to the human delta-opioid receptor produces distinctly different conformational states distinguishable by plasmon-waveguide resonance spectroscopy. J Pept Res. 2002;60:322-328.
125. Alves ID, Ciano KA, Boguslavski V, et al. Selectivity, cooperativity, and reciprocity in the interactions between the delta-opioid receptor, its ligands, and G-proteins. J Biol Chem. 2004a;279:44673-44682.
126. Alves ID, Cowell SM, Salamon Z, Devanathan S, Tollin G, Hruby VJ. Different structural states of the proteolipid membrane are produced by ligand binding to the human delta-opioid receptor as shown by plasmon-waveguide resonance spectroscopy. Mol Pharmacol. 2004b;65:1248-1257.
127. Tramontano A, Morea V. Exploiting evolutionary relationships for predicting protein structures. Biotechnol Bioeng. 2003;84:756-762.
128. Bates PA, Kelley LA, MacCallum RM, Sternberg MJ. Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins. 2001;39-46.
129. Li X, Jacobson W, Friesner RA. High-resolution prediction of protein helix positions and orientations. Proteins. 2004;55:368-382.
130. Evers A, Gohlke H, Klebe G. Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. J Mol Biol. 2003;334:327-345.
131. Ward SD, Hamdan FF, Bloodworth TM, Wess J. Conformational changes that occur during M3 muscarinic acetylcholine receptor activation probed by the use of an in situ disulfide cross-linking strategy. J Biol Chem. 2002;277:2247-2257.
132. 2+ on the beta2 adrenergic receptor. J Biol Chem. 2003;278:352-356.
133. Elling CE, Thirstrup K, Holst B, Schwartz TW. Conversion of agonist site to metal-ion chelator site in the beta(2)-adrenergic receptor. Proc Natl Acad Sci USA. 1999;96:12322-12327.
134. Holst B, Elling CE, Schwartz TW. Partial agonism through a zinc-ion switch constructed between transmembrane domains III and VII in the tachykinin NK(1) receptor. Mol Pharmacol. 2000;58:263-270.
135. Lagerstrom MC, Klovins J, Fredriksson R, et al. High affinity agonistic metal ion binding sites within the melanocortin 4 receptor illustrate conformational change of transmembrane region 3. J Biol Chem. 2003;278:51521-51526.
136. Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des, 2001;15:411-428.
137. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267:727-748.
138. Rarey M, Wefing S, Lengauer T. Placement of medium-sized molecular fragments into active sites of proteins. J Comput Aided Mol Des. 1996;10:41-54.
139. Taylor RD, Jewsbury PJ, Essex JW. FDS: flexible ligand and receptor docking with a continuum solvent model and soft-core energy function. J Comput Chem. 2003;24:1637-1656.
140. Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47:1750-1759.
141. Venkatachalam CM, Jiang X, Oldfield T, Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model. 2003;21:289-307.
142. Cavasotto CN, Abagyan RA. Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol. 2004;337:209-225.
143. Perola E, Walters WP, Charifson PS. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins. 2004;56:235-249.
144. Halperin I, Ma B, Wolfson H, Nussinov R. Principles of docking an overview of search algorithms and a guide to scoring functions. Proteins. 2002;47:409-443.
145. Kontoyianni M, McClellan LM, Sokol GS. Evaluation of docking performance: comparative data on docking algorithms. J Med Chem. 2004;47:558-565.
146. Carlson HA, McCammon JA. Accommodating protein flexibility in computational drug design. Mol Pharmacol. 2000;57:213-218.
147. Evers A, Klebe G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J Med Chem. 2004b;47:5381-5392.
148. Heyl DL, Mosberg HI. Modification of the Phe3 aromatic moiety in delta receptor-selective dermorphin/deltorphin-related tetrapeptides: effects on opioid receptor binding. Int J Pept Protein Res. 1992;39:450-457.
149. Sebastian A, Bidlack JM, Jiang Q, et al. 14 beta-[(p-nitrocinnamoy 1)amino]morphinones, 14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinones, and their codeinone analogues: synthesis and receptor activity. J Med Chem. 1993;36:3154-3160.
150. Sagara T, Egashira H, Okamura M, Fujii I, Shimohigashi Y, Kanematsu K. Ligand recognition in mu opioid receptor: experimentally based modeling of mu opioid receptor binding sites and their testing by ligand docking. Bioorg Med Chem. 1996;4:2151-2166.
151. Chabre M, Breton J. Orientation of aromatic residues in rhodopsin: rotation of one tryptophan upon the meta I to meta II transition after illumination. Photochem Photobiol. 1979;30:295-299.
152. Baneres JL, Martin A, Hullot P, Girard JP, Rossi JC, Parello J. Structure-based analysis of GPCR function: conformational adaptation of both agonist and receptor upon leukotriene B4 binding to recombinant BLT1. J Mol Biol. 2003-329:801-814.
153. Ruprecht JJ, Mielke T, Vogel R, Villa C, Schertler GF. Electron crystallography reveals the structure of metarhodopsin I. EMBO J. 2004;23:3609-3620.
154. Sammes PG, Taylor JB. Opioid receptors. In: Hansch C, ed. Comprehensive Medicinal Chemistry. Oxford, UK: Pergamon Press; 1990:805-844.
155. Schiller PW, Weltrowska G, Nguyen TM-D, Lemieux C, Chung NN, Lu Y. Conversion of μ-, δ- and κ-receptor selective opioid peptide agonists into μ-, δ-, and κ-receptor selective antagonists. Life Sci. 2003;73:691-698.
156. Huang P, Kim S, Loew G. Development of a common 3D pharmacophore for delta-opioid recognition from peptides and non-peptides using a novel computer program. J Comput Aided Mol Des. 1997;11:21-28.
157. Filizola M, Villar HO, Loew GH. Molecular determinants of nonspecific recognition of delta, mu, and kappa opioid receptors. Bioorg Med Chem. 200la;9:69-76.
158. Filizola M, Villar HO, Loew GH. Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties. J Comput Aided Mol Des. 2001b;15:297-307.
159. Bernard D Jr, Coop A Jr, MacKerell AD Jr. 2D conformationally sampled pharmacophore: a ligand-based pharmacophore to differentiate delta opioid agonists from antagonists. J Am Chem Soc. 2003;125:3101-3107.